Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;131(6):E1941-E1949.
doi: 10.1002/lary.29343. Epub 2021 Jan 6.

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Douglas R Sidell  1   2 Karthik Balakrishnan  1   2 Simon R Best  3 Karen Zur  4 Julia Buckingham  5 Alessandro De Alarcon  6 Fuad M Baroody  7 Jonathan M Bock  8 Emily F Boss  9 Charles M Bower  10 Paolo Campisi  11 Sharon F Chen  12 Jeffrey M Clarke  13 Kevin D Clarke  14 Alejandro Cocciaglia  15 Robin T Cotton  6 Giselle Cuestas  16 Kara L Davis  17 Victor H DeFago  18 Frederik G Dikkers  19 Ines Dossans  20 Walter Florez  21 Elizabeth Fox  22 Aaron D Friedman  23 Nazaneen Grant  24 Osama Hamdi  25 Norman D Hogikyan  26 Kaalan Johnson  27 Liane B Johnson  28 Romaine F Johnson  29 Peggy Kelly  30 Adam M Klein  31 Claire M Lawlor  32 Nicolas Leboulanger  33 Alejandro G Levy  34 Derek Lam  35 Greg R Licameli  36 Steve Long  37 David G Lott  38 Dayse Manrique  39 James Scott McMurray  40 Kara D Meister  1   2 Anna H Messner  41 Michael Mohr  42 Pamela Mudd  32 Anthony J Mortelliti  43 Daniel Novakovic  44 Julian Ongkasuwan  45 Shazia Peer  46 Krysztof Piersiala  47 Jeremy D Prager  30 Seth M Pransky  48 Diego Preciado  32 Tiffany Raynor  49 Rico N P M Rinkel  50 Hugo Rodriguez  51 Verónica P Rodríguez  16 John Russell  52 María Laura Scatolini  51 Patrick Scheffler  1 David F Smith  53 Lee P Smith  54 Marshall E Smith  55 Richard J H Smith  56 Abraham Sorom  57 Amalia Steinberg  58 John A Stith  59 Dana Thompson  60 Jerome W Thompson  61 Patricio Varela  62 David R White  63 Andre M Wineland  9 Christina J Yang  64 Carlton J Zdanski  65 Craig S Derkay  66
Affiliations

Systemic Bevacizumab for Treatment of Respiratory Papillomatosis: International Consensus Statement

Douglas R Sidell et al. Laryngoscope. 2021 Jun.

Abstract

Objectives/hypothesis: The purpose of this study is to develop consensus on key points that would support the use of systemic bevacizumab for the treatment of recurrent respiratory papillomatosis (RRP), and to provide preliminary guidance surrounding the use of this treatment modality.

Study design: Delphi method-based survey series.

Methods: A multidisciplinary, multi-institutional panel of physicians with experience using systemic bevacizumab for the treatment of RRP was established. The Delphi method was used to identify and obtain consensus on characteristics associated with systemic bevacizumab use across five domains: 1) patient characteristics; 2) disease characteristics; 3) treating center characteristics; 4) prior treatment characteristics; and 5) prior work-up.

Results: The international panel was composed of 70 experts from 12 countries, representing pediatric and adult otolaryngology, hematology/oncology, infectious diseases, pediatric surgery, family medicine, and epidemiology. A total of 189 items were identified, of which consensus was achieved on Patient Characteristics (9), Disease Characteristics (10), Treatment Center Characteristics (22), and Prior Workup Characteristics (18).

Conclusion: This consensus statement provides a useful starting point for clinicians and centers hoping to offer systemic bevacizumab for RRP and may serve as a framework to assess the components of practices and centers currently using this therapy. We hope to provide a strategy to offer the treatment and also to provide a springboard for bevacizumab's use in combination with other RRP treatment protocols. Standardized delivery systems may facilitate research efforts and provide dosing regimens to help shape best-practice applications of systemic bevacizumab for patients with early-onset or less-severe disease phenotypes.

Level of evidence: 5 Laryngoscope, 131:E1941-E1949, 2021.

Keywords: Avastin; Systemic bevacizumab; consensus.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding, financial relationships, or conflicts of interest to disclose.

References

    1. Derkay CS, Bluher AE. Recurrent respiratory papillomatosis: update 2018. Curr Opin Otolaryngol Head Neck Surg 2018;26:421–425. - PubMed
    1. Nagel S, Busch C, Blankenburg T, Schütte W. Treatment of respiratory papillomatosis–a case report on systemic treatment with bevacizumab. Pneumologie 2009;63:387–389. - PubMed
    1. San Giorgi MRM, Aaltonen LM, Rihkanen H, et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope 2017;127:1826–1831. - PubMed
    1. Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 2000;126:935–939. - PubMed
    1. Larson DA, Derkay CS. Epidemiology or recurrent respiratory papillomatosis. APMIS 2010;118:450–454. - PubMed

Publication types

MeSH terms

Supplementary concepts